Human Genome Sciences has rejected an unsolicited M&A bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector recently swept by M&A activity.
The U.S. pioneer of gene-based drug discovery, which sells a new drug for lupus with GSK, said on Thursday the offer of $13 per share, made in a letter on April 11, did not reflect the value inherent in the company.
It has hired Goldman Sachs and Credit Suisse to help explore new strategic M&A alternatives, including a possible sale. GSK has been invited to participate in that process.
Read the full story at Reuters
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
Report: Partnering Deals and Alliances with GlaxoSmithKline
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity